SCHEMBL3155161

SCHEMBL3155161

NC(=O)c1cccc(C[CH]C(=O)NCc2ccc(N)nc2)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39
GABRA6 Q16445 1/20 0.39
GABRG1 Q8N1C3 1/20 0.39
GABRG3 Q99928 1/20 0.39
GABRQ Q9UN88 1/20 0.39
AURKA O14965 6/20 0.38
RPS6KB1 P23443 6/20 0.38
PDPK1 O15530 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3140045 0.89 NAMPT (0.43) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3144699 0.87 NAMPT (0.39) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3156484 0.87 F2 (0.40) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3149495 0.85 NAMPT (0.40) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3153906 0.83 F2 (0.46) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3144720 0.81 HDAC1 (0.39) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3153349 0.81 NAMPT (0.40) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3153093 0.81 F2 (0.40) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3148803 0.81 VNN1 (0.41) NAMPTGABRPGABRDGABRA1GABRB1
SCHEMBL3149776 0.80 NAMPT (0.43) NAMPTGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100076015-A1 Aminopyridine Derivatives VANTIA LIMITED (GB) 2010-03-25 US disclosed
WO-2009133348-A1 AMINOPYRIDINE DERIVATIVES VANTIA LIMITED (GB) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076015-A1 Aminopyridine Derivatives CHRM1, ARG1, ARG2 NAMPT 1657/4885GABRP 1565/4885GABRD 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.